Metadata record for the article: Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

<b>Summary</b>This metadata record provides details of the data supporting the claims of the related article: “Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia”.The related study aimed to generate a murine pro-B cell model of ATF7IP-JAK2 with acquired resistance to multiple type-I JAK inhibitors. Type of data: exome sequencing data; flow cytometry; computational modelling Subject of data: <i>Homo sapiens; </i>antibodies; eukaryotic cell lines (parental Ba/F3 cell line)Recruitment: Cryopreserved bone marrow mononuclear cell samples from Ph-like B-ALL patients were obtained from the Children’s Cancer Institute Australia (CCIA), SA Pathology/Royal Adelaide Hospital, Australasian Leukaemia &amp; Lymphoma Group (ALLG) tissue bank, or Queensland Children’s Tumour Bank. <b>Data access</b>The exome sequencing data are openly available in the <i>NCBI Sequence Read Archive</i> via the following accession: https://identifiers.org/ncbi/bioproject:PRJNA741841. All additional data files underlying the Figures and Supplementary Figures of the related article are shared openly as part of this <i>figshare </i>data record. Files underlying Figures:ATF7IP-JAK2_BaF3_pSTAT5Timecourse_Histograms.pdfATF7IP-JAK2_RuxR_TypeIJAKInhib_CellViabilities.xlsxG993A_JAK2r_BaF3_GFP.pdfNonMutG993A_BaF3_RUX_CellViabilities.xlsxNotMutG993A_TypeIJAKInhib_pSTAT5.xlsxATF7IP-JAK2_RuxR_CHZ868_CellViabilities.xlsxNonMutG993ABaF3_pSTAT5_CHZ868.pdf Files underlying Supplementary Figures:ATF7IP-JAK2_BaF3_GFP-Layout.pdfUnprocessed_WBImages.pdfATF7IP-JAK2_RuxR_TrypanCounts.xlsxEmptyVector_BaF3_JAKInhib_CellViabilities.xlsxJAK2r_BaF3_GFP.pdfNonMut_JAK2_BaF3_HAExp.pdfCellProliferation_Luminescence.xlsxNonMutG993A_pSTAT135Phosphoflow.pdfJAK2NonMutG993A_CellProliferation_Luminescence.xlsxNonMutG993A_pAKTpERK_MFI.xlsx <b>Corresponding author(s) for this study</b>Professor Deborah White, Director: Cancer Program. Deputy Theme Leader: Precision Medicine. South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000; [e-mail]<br> <b>Study approval </b>The use of samples was approved by Central Adelaide Local Health Network and the Royal Adelaide Hospital Human Research Ethics Committee. Samples were obtained with informed consent for prospective unspecified medical research, and to perform laboratory-based assays on existing specimens. All the participants were required to provide informed consent for their samples to be used in accordance with the Declaration of Helsinki.